Development of thrombocytosis in HIV+ drug users: impact of antiretroviral therapy

Míguez‐Burbano, Maria José; Burbano, Ximena; Rodríguez, Allan; Lecusay, Robert; Rodríguez, Nohra Cecilia; Shor‐Posner, Gail

doi:10.1080/0953371027984

Cited by 23 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These abnormalities have been associated with thromboses involving veins and arteries and seem to be related to HAART regimens that include PI 77 . Thrombocytosis has been reported in 9% of patients receiving HAART, with cardiovascular complications in up to 25% of cases 78 .…”

Section: Haart-associated Coagulation Disordersmentioning

confidence: 99%

Cardiovascular complications in the acquired immunodeficiency syndrome

Bárbaro

Silva

2009

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Section: Haart-associated Coagulation Disordersmentioning

confidence: 99%

Cardiovascular complications in the acquired immunodeficiency syndrome

Bárbaro

Silva

2009

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

“…41,43,44 Thrombocytosis has been reported in 9% of patients receiving HAART, with cardiovascular complications in up to 25% of the cases. 45 According to the Pavia Consensus Statement, the routine evaluation of coagulation parameters is probably not advisable until the benefit of widespread screening is assessed in prospective studies. However, clinicians should be aware of the increased risk of coagulopathies in HIV infected patients receiving HAART, especially in those with HAART-associated metabolic syndrome.…”

Section: Haart and Coagulation Disordersmentioning

confidence: 99%

Highly Active Antiretroviral Therapy–Associated Metabolic Syndrome: Pathogenesis and Cardiovascular Risk*

Bárbaro

2006

American Journal of Therapeutics

View full text Add to dashboard Cite

The introduction of highly active antiretroviral therapy (HAART) has significantly modified the course of HIV disease, with longer survival and improved quality of life of HIV-infected subjects. However, HAART regimens, especially those including protease inhibitors (PIs) have been shown to cause in a high proportion of HIV-infected patients a metabolic syndrome that may be associated with an increased risk of cardiovascular disease (about 1.4 cardiac events per 1,000 years of therapy according to the Framingham score). Metabolic features associated with somatic changes (lipodystrophy/lipoatrophy) include dyslipidemia (about 70% of patients), insulin resistance (elevated C-peptide and insulin), type 2 diabetes mellitus (8%-10% of the patients), hypertension (up to 75% of patients), coagulation abnormalities (25% of patients), lactic acidemia, and elevated hepatic transaminases (nonalcoholic steatohepatitis). HAART-associated metabolic syndrome is an increasingly recognized clinical entity. A better understanding of the molecular mechanisms responsible for this syndrome will lead to the discovery of new drugs that will reduce the cardiovascular risk in patients under HAART. A careful stratification of the cardiovascular risk and cardiovascular monitoring of patients under HAART is needed according to the most recent clinical guidelines.

show abstract

“…These abnormalities are associated with thromboses involving veins and arteries and seem to be related to HAART regimens that include PIs [36] . Thrombocytosis has been reported in 9% of patients who are receiving HAART, with cardiovascular complications in up to 25% of cases [37] .…”

Section: Hiv-associated Cardiology Issuesmentioning

confidence: 99%

Heart and HAART: Two sides of the coin for HIV-associated cardiology issues

Bárbaro¹

2010

WJC

View full text Add to dashboard Cite

The introduction of highly active antiretroviral therapy (HAART) has generated a contrast in the cardiac manifestations of acquired immunodeficiency syndrome. In developed countries, we have observed an approximately 30% reduction in the prevalence of human immunodeficiency virus (HIV)-associated cardiomyopathy, possibly related to a reduction of opportunistic infections and myocarditis. In developing countries, however, where the availablity of HAART is limited and the pathogenic impact of nutritional factors is significant, we have observed an approximately 32% increase in the prevalence of HIV-associated cardiomyopathy and a related high mortality rate from congestive heart failure. Also, some HAART regimens in developed countries, especially those including protease inhibitors, have been shown to cause, in a high proportion of HIV-infected patients, an iatrogenic metabolic syndrome (HIV-lipodystrophy syndrome) that is associated with an increased risk of cardiovascular events related to a process of accelerated atherosclerosis, even in young HIV-infected people. Careful cardiac screening is warranted for patients who are being evaluated for, or who are receiving, HAART regimens, particularly for those with known underlying cardiovascular risk factors. A close collaboration between cardiologists and infectious disease specialists is needed for decisions regarding the use of antiretrovirals, for a careful stratification of cardiovascular risk factors, and for cardiovascular monitoring of HIV-infected patients receiving HAART, according the most recent clinical guidelines.

show abstract

Development of thrombocytosis in HIV+ drug users: impact of antiretroviral therapy

Cited by 23 publications

References 3 publications

Cardiovascular complications in the acquired immunodeficiency syndrome

Cardiovascular complications in the acquired immunodeficiency syndrome

Highly Active Antiretroviral Therapy–Associated Metabolic Syndrome: Pathogenesis and Cardiovascular Risk*

Heart and HAART: Two sides of the coin for HIV-associated cardiology issues

Contact Info

Product

Resources

About